A Novel Lonidamine Derivative Targeting Mitochondria to Eliminate Cancer Stem Cells by Blocking Glutamine Metabolism

Investigators reported a novel derivative of lonidamine, namely HYL001, which selectively and potently inhibited CSCs by targeting mitochondria.
[Pharmacological Research]
Full ArticleGraphical Abstract

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News